Pregled bibliografske jedinice broj: 724432
Useful Supplement to the Best Practice of Using Levosimendan in a Heart Surgery Patient ; 2.5 mg Intravenous Bolus for Cardiopulmonary Resuscitation during Perioperative Cardiac Arrest?
Useful Supplement to the Best Practice of Using Levosimendan in a Heart Surgery Patient ; 2.5 mg Intravenous Bolus for Cardiopulmonary Resuscitation during Perioperative Cardiac Arrest? // Journal of cardiothoracic and vascular anesthesia, 27 (2013), 6; e75-e77 doi:10.1053/j.jvca.2013.07.018 (podatak o recenziji nije dostupan, pismo uredniku, stručni)
CROSBI ID: 724432 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Useful Supplement to the Best Practice of Using Levosimendan in a Heart Surgery Patient ; 2.5 mg Intravenous Bolus for Cardiopulmonary Resuscitation during Perioperative Cardiac Arrest?
Autori
Carev, Mladen ; Karanović, Nenad ; Kocen, Dubravka ; Bulat, Cristijan
Izvornik
Journal of cardiothoracic and vascular anesthesia (1053-0770) 27
(2013), 6;
E75-e77
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, stručni
Ključne riječi
levosimendan ; cardiac surgical procedures ; cardiopulmonary resuscitation ; treatment outcome
Sažetak
It is a letter to the editor regarding the excellent clinical review of “new” inotrope levosimendan, which was published in the aforementioned journal (Toller W, L Algotsson, Guarracino F, et al: Perioperative use of levosimendan: best practice and operational settings. Anesth Analg . 2013 ; 27: 361-366.) Importance of our lette: Levosimendan is a potent inotrope that is being increasingly used, especially in cardiac anesthesia. However, its use is relatively new and there are still many clinical concerns. This paper describes for the first time application of levosimendan in a completely new clinical circumstances, i.e. in cardiopulmonary resuscitation after cardiac surgery. Through this letter to editor we presented clinical course of 4 cardiac surgery patients, and also described techniques and dosage of levosimendan. To be noted is that levosimendan in these patients was used as the "last chance", but with a very good clinical effect. We believe that this article will be a good "trigger" for the use of this valuable drug in an entirely new, but very specific indication, i.e. resuscitation.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE